Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study-Reference-Cited by-同舟云学术

Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study

Published:2019-06 Issue:10188 Volume:393 Page:2303-2311
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Smolen Josef S,Pangan Aileen L,Emery Paul,Rigby William,Tanaka Yoshiya,Vargas Juan Ignacio,Zhang Ying,Damjanov Nemanja,Friedman Alan,Othman Ahmed A,Camp Heidi S,Cohen Stanley

Publisher

Elsevier BV

Subject

General Medicine

Reference29 articles.

1. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update;Smolen;Ann Rheum Dis,2017

2. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis;Singh;Arthritis Rheumatol,2016

3. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial;Emery;Lancet,2008

4. Limited efficacy of conventional DMARDs after initial methotrexate failure in patients with recent onset rheumatoid arthritis treated according to the disease activity score;van der Kooij;Ann Rheum Dis,2007

5. Long-term tolerability of methotrexate at doses exceeding 15 mg per week in rheumatoid arthritis;Schnabel;Rheumatol Int,1996

Cited by 275 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. JAK inhibitor selectivity: new opportunities, better drugs?;Nature Reviews Rheumatology;2024-09-09

2. Upadacitinib to improve anxiety in patients with adalimumab-treated psoriatic arthritis: study protocol for a randomized controlled trial;Trials;2024-09-05

3. Adverse cardiovascular events in rheumatoid arthritis patients treated with JAK inhibitors: An analysis of postmarketing spontaneous safety reports;Seminars in Arthritis and Rheumatism;2024-08

4. JAK Inhibitors in Rheumatoid Arthritis: Immunomodulatory Properties and Clinical Efficacy;International Journal of Molecular Sciences;2024-07-30

5. Upadacitinib monotherapy versus methotrexate monotherapy in patients with rheumatoid arthritis: efficacy and safety through 5 years in the SELECT-EARLY randomized controlled trial;Arthritis Research & Therapy;2024-07-29